Immunic reveals long-term data supporting potential of MS drug vidofludimus calciumProactive Investors • 06/24/25
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisPRNewsWire • 06/24/25
Immunic showcases MS drug data at BIO International Convention in Boston - ICYMIProactive Investors • 06/21/25
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trialsProactive Investors • 06/05/25
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MSPRNewsWire • 06/05/25
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public OfferingPRNewsWire • 06/03/25
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public OfferingPRNewsWire • 05/29/25
Immunic reports reduced disability worsening in progressive multiple sclerosis trialProactive Investors • 04/30/25
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER TrialPRNewsWire • 04/30/25
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares HigherSeeking Alpha • 04/28/25
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsPRNewsWire • 04/10/25
Immunic announces pricing of $5.1M direct offering to support clinical pipelineProactive Investors • 04/09/25
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsPRNewsWire • 04/09/25
Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forumProactive Investors • 02/26/25